Anaves Life Sciences Trial Results of Blarcamesine
Anavex Life Sciences (AVXL) presented comprehensive results from a Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, significantly slowed clinical decline in people with early Alzheimer's disease (AD).

The data presentation was made by Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman . . .